{'fraction_non_alphanumeric': 0.01726844583987441, 'fraction_numerical': 0.014913657770800628, 'mean_word_length': 5.640625, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparison of Zomepirac, APC with Codeine, Codeine and Placebo in the Treatment of Moderate and Severe Postoperative Pain

JSBELL1 has chronicled the long search for an analgesic of sufficient efficacy to alleviate pain from disease, trauma, or surgery without the concomitant potential for drug tolerance, abuse, or addiction. This study and recent companion investigations suggest that zomepirac may represent a significant step toward this objective. Zomepirac is rapidly and completely absorbed in man following oral administration. The peak plasma concentration of zomepirac is achieved in approximately 1 hour, and the terminal plasma half-life is approximately 4 hours.2 The safety and efficacy of zomepirac have been explored in patients suffering moderate to severe pain from malignancy, oral surgery, osteoarthritis, muscle contraction headache, episiotomy, and a variety of general and orthopedic surgical procedures.31 Cooper et al.3 have shown that an oral dose of 25 mg zomepirac provides analgesia approximately equivalent to 650 mg aspirin, whereas 100 mg zomepirac afforded significantly greater analgesia and had a longer duration of action than 650 mg aspirin. No potential dependence liability for zomepirac has been demonstrated in preclinical studies,8